Continuous expression of activated Factor VII (FVIIa) via gene transfer is a potential therapeutic approach for hemophilia patients with or without inhibitory antibodies to human Factor VIII (FVIII) or IX (FIX). Here, we investigate whether gene transfer of an engineered canine FVIIa (cFVIIa) transgene can effect hemostasis in a canine model of hemophilia, a good predictor of efficacy of hemophilia treatments. Purified recombinant cFVIIa exhibited 12-fold higher tissue factor-dependent activity than purified recombinant zymogen cFVII. Subsequently, we generated a serotype 8 recombinant adeno-associated viral (AAV8) vector expressing cFVIIa from a liver-specific promoter.
Abstract
Continuous expression of activated Factor VII (FVIIa) via gene transfer is a potential therapeutic approach for hemophilia patients with or without inhibitory antibodies to human Factor VIII (FVIII) or IX (FIX). Here, we investigate whether gene transfer of an engineered canine FVIIa (cFVIIa) transgene can effect hemostasis in a canine model of hemophilia, a good predictor of efficacy of hemophilia treatments. Purified recombinant cFVIIa exhibited 12-fold higher tissue factor-dependent activity than purified recombinant zymogen cFVII. Subsequently, we generated a serotype 8 recombinant adeno-associated viral (AAV8) vector expressing cFVIIa from a liver-specific promoter.
Vector delivery via the portal vein in hemophilia A and B dogs was well-tolerated and long-term expression of cFVIIa resulted in a shortening of the prothrombin time, partial correction of the whole blood clotting time and thromboelastography parameters, and a complete absence of spontaneous bleeding episodes. No evidence of hepatotoxicity, thrombotic complications or inhibitory immune response was found. These data provide the first evidence for in vivo efficacy and safety of continuously expressed FVIIa as a FVIII/FIX-bypassing agent in a large animal model of hemophilia, avoiding the risk of inhibitor formation associated with bolus FVIII or FIX infusion.
Introduction
Despite the availability of plasma-derived and recombinant human Factor VIII (rhFVIII) or Factor IX (rhFIX) as therapeutics for hemophilia, inhibitor formation (20-30% in severe hemophilia A; ~5% in severe hemophilia B 1,2 ) remains a serious complication in a substantial fraction of these patients. Pharmacologic doses of activated recombinant human Factor VII (rhFVIIa) administered in multiple doses 3 or a single high-dose 4 has been successful in effecting hemostasis in such patients as well as in patients with platelet disorders 5 and FVII deficiency. 6, 7 Dosing of rhFVIIa has also demonstrated efficacy in short-term secondary prophylaxis. 8 However, the need for repeated injections (daily dosing) because of the short plasma half-life may limit its convenience for prolonged periods of prophylaxis.
In an effort to bypass these drawbacks, we have previously demonstrated that a
Factor VII transgene engineered to be secreted in its activated form (FVIIa) can correct the hemostatic parameters in mouse models of hemophilia A (HA) and B (HB), following either AAV delivery 9 , or in transgenic animals. 10 However, a necessary step preceding human application is the demonstration of safety and efficacy in a large animal (canine)
model. This important hemophilia model closely resembles the human disorder in terms of size, physiology and the genetic determinants of immune response, since it is outbred instead of inbred. 11 Additionally, it has been a good predictor of efficacy in hemophilia treatments. [12] [13] [14] [15] 
Materials and Methods

Plasmid construction, protein purification and AAV production
A pcDNA3-based (Invitrogen, Carlsbad, CA) plasmid vector containing the canine Factor VII (cFVII) cDNA 18 was used to generate cFVIIa by PCR-mutagenesis (by insertion of the Arg-Lys-Arg-Arg-Lys-Arg [RKRRKR] sequence at position 152 in the mature cFVII sequence), as previously described. 9 In order to purify cFVII or cFVIIa, a C-terminal epitope tag (HPC4) was added to the translated peptide sequence, as previously described 9 , thus generating cFVII-HPC4 and cFVIIa-HPC4. Stable cell lines based on human embryonic kidney cells (HEK-293) were generated by transfection and selection in G418, and proteins were purified from vitamin-K supplemented conditioned medium using a one-step immunoaffinity column (against the HPC4 epitope), as previously described. 9 Protein concentration was determined spectrophotometrically using a molecular weight of 50,000 and an extinction coefficient (E 280 0.1% ) of 1.39. The AAV plasmid used for vector production directed expression of cFVIIa (without the HPC4 tag) from a liver-specific promoter (human α 1 antitrypsin, hAAT) and enhancer (4 copies of the apolipoprotein E [apoE] enhancer), as previously described. 9 Production of serotype 8
AAV vector was performed by triple transfection, essentially as previously described.
9
Clotting assays for purified proteins Following incubation at 37ºC for 3 min, 25 µl of 25 mM CaCl 2 were added and time to clot was recorded. For both PT and aPTT, purified recombinant proteins were compared using a reference standard curve of human recombinant FVIIa (rhFVIIa). In these experimental assay systems, normalization of canine FVII-deficient plasma PT was observed using ~70 ng/ml of cFVIIa and ~200 ng/ml rhFVIIa. Normalization of the HA and HB aPTT was observed at 20 µg/ml of either cFVIIa or rhFVIIa.
Clotting assays for mouse and dog experiments
PT and aPTT assays for mouse or canine plasma samples were performed by recording the time to clot after mixing 25 µl of sample (diluted 40 fold [canine] or 160 fold [mouse] in TBS-BSA), 25µl of human FVII-deficient plasma and, following incubation at 37ºC, addition of 100 µl of Innovin. Activated partial thromboplastin time assays for mouse plasma samples were performed as described above, but using undiluted aPTT reagent.
Whole blood clotting time (WBCT) and was performed essentially as previously described. 16 Thromboelastography was performed as previously described 19 using freshly drawn blood and initiating coagulation using 1 in 200,000 dilution of Innovin.
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Comparison in thromboelastography parameters between the AAV-treated dogs and normal or untreated HA/HB dogs was performed using data points from at least 1 week after the last plasma infusion, following gene transfer.
cFVIIa antigen determination
The concentration of the expressed cFVIIa in canine plasma was determined from clotting activity using the STAclot kit (Diagnostica Stago), as previously described for rhFVIIa. 20 . Briefly, a standard curve of increasing cFVIIa concentration (50 µl sample) in dilution buffer (50 mM PIPES, 100 mM NaCl, 2 mM EDTA, 0.1% BSA, pH7.2) was generated using 50 µl of human FVII-deficient plasma and 50 µl of recombinant soluble human TF/phospholipid mixture. Following a 3 min incubation at 37ºC, 50 µl of 25 mM 10-or 50-fold in dilution buffer and clot time was determined as described above.
Concentration of cFVIIa in those samples was derived from the obtained standard curve.
Canine FVIIa levels in normal, untreated HA or HB dogs were determined using at least 4 individual samples (in the case of HA or HB) or by using a pooled sample from at least 4 dogs (in the case of normal dogs).
D-dimer, fibrinogen and thrombin-antithrombin assays
D-dimer determination was performed in duplicate on citrated plasma dog samples using the enzyme-linked immunosorbent assay (ELISA)-based Asserachrom D-Di kit (Diagnostica Stago). 21 Fibrinogen levels in citrated dog plasma samples were determined in duplicate using a clotting-based assay (Clauss method, Dade-Behring) that utilized a human plasma standard as a reference. 21 Assays were performed according to the manufacturer's instructions but using ½ the volume of each reagent. Thrombinantithrombin (TAT) assays were performed in duplicate on citrated plasma using the of the University of North Carolina (UNC) at Chapel Hill colony was performed as previously described. 22 Antibodies against AAV8 or cFVIIa were detected by ELISA using either AA8 or recombinant cFVIIa coated plates, essentially as previously 
Statistical analysis
An unpaired two-tailed Student's t or a two-sided Fisher's exact test (for analysis of bleeding episodes) was used for statistical analysis with a P <0.05 indicating statistical significance.
Results
Purification of recombinant zymogen cFVII and cFVIIa
Initially, we generated HEK-293-based stable cell lines expressing zymogen cFVII or cFVIIa, both proteins containing a C-terminal epitope tag (HPC4) for immunoaffinity purification ( Figure 1A ). 9 Recombinant zymogen cFVII and cFVIIa were successfully purified from vitamin K-supplemented conditioned medium. In contrast to zymogen cFVII, which was purified in a single-chain form (indicating lack of auto-activation during purification), cFVIIa was purified almost exclusively in the two-chain, fully activated form ( Figure 1B ). The lower molecular weight bands observed at 10-16 kDa are most likely degradation products, as have been previously observed in human recombinant FVIIa preparations. 23, 24 Although the heavy and light chains of cFVIIa exhibited differential staining with Coomassie blue, this is commonly found in human 23, 24 as well as murine FVIIa preparations.
9,25
In vitro activity of zymogen cFVII and cFVIIa Subsequently, we investigated the proteolytic activity of zymogen cFVII and cFVIIa, using human recombinant FVIIa (rhFVIIa) as a reference standard. Using pooled canine plasma from FVII-deficient dogs 18 , we determined the TF-dependent activity of cFVIIa using relipidated recombinant human TF (Innovin). In this system, zymogen cFVII exhibited very low activity (~20% of rhFVIIa, P<0.00001 vs. rhFVIIa; Figure 1C ) in contrast to cFVIIa which exhibited ~240% of rhFVIIa (P<0.00001 vs. rhFVIIa; Figure   1C ), ~12 fold higher activity than zymogen cFVII. In a TF-independent aPTT-based assay using HA or HB canine plasma, cFVIIa exhibited a slightly increased (HA, P=0.044) or comparable (HB, P=0.44) activity relative to rhFVIIa ( Figure 1D ). In that assay, zymogen cFVII had negligible activity ( Figure 1D ). It is possible that the disparity in extrinsic and intrinsic activity of cFVIIa relative to rhFVIIa is due to the use of human relipidated TF. Collectively, these data demonstrate that cFVII can be engineered so that it is secreted in a two-chain, biologically active form.
Efficacy of AAV-mediated cFVIIa gene transfer in hemophilic mice and dogs
We generated a serotype 8 AAV vector (AAV8-cFVIIa, Figure 2A ) directing expression of cFVIIa via a liver-specific promoter, similar to our previous studies in mice. 9, 10 The cFVIIa transgene in this AAV vector did not contain the C-terminal epitope tag (HPC4).
In preliminary experiments designed to test the functionality of the AAV vector, we Since the AAV8-cFVIIa vector dose that would result in hemostatic efficacy in hemophilic dogs was unknown, we initially infused a HB male dog (HB-1-J10) with 2.06 E13 v.g./kg via the portal vein ( Figures 2C-D, respectively) . Subsequently, we observed a long-term, stable reduction, well below pre-infusion times for both WBCT and PT ( Figures 2C-D, respectively). This was a result of sustained cFVIIa gene expression that ranged between 1.3 and 2.6 µg/ml (P<0.03 vs. normal or untreated HA dogs; Figure 2E ). As expected, the treated HB-1-J10 dog that did not exhibit a measurable reduction in the PT did not exhibit a change in cFVIIa antigen levels ( Figure 2E. ).
To further demonstrate efficacy, we performed thromboelastography analysis of whole blood from the treated HA dogs. We observed a greatly improved clot dynamics profile (data not shown) and a sustained, near-normalization of the reaction time ( 
J10 dog showed a modest improvement in these thromboelastography parameters compared to untreated HB controls (data not shown).
AAV-cFVIIa treated hemophilic dogs do not exhibit spontaneous bleeding episodes
Since dogs with hemophilia exhibit approximately 5-6 spontaneous bleeding episodes per year 27, 28 , we utilized the number of spontaneous bleeds as a clinically relevant efficacy endpoint. Control untreated HA and HB dogs that were observed concurrently within this study exhibited 12 and 21 spontaneous bleeds in 36 and 60 cumulative months of observation, respectively ( Table 2 ). In a cumulative 34 months (HB) and 45 months (HA) of observation, the AAV8-cFVIIa treated dogs did not exhibit any spontaneous bleeding episodes, in contrast to the expected 15 (HB) and 21 (HA) episodes (P<0.002 vs.
historical data in this dog colony 27, 28 or the paired concurrent controls, Table 2 ). The lowest dosed HB dog exhibited 3 non-spontaneous bleeds within the first 8 months post AAV vector administration and each after a hemostatic challenge (the initial surgery for vector delivery, a liver biopsy performed to study cFVIIa expression, and dog fighting; normal canine plasma was administered daily for each episode for up to 3 days).
Remarkably, despite the lack of appreciable changes in WBCT, PT or cFVIIa expression in this dog (up to 34 months of observation, ongoing), AAV8-cFVIIa administered at vector doses that did not raise the circulating levels of cFVIIa resulted in a measurable phenotypic impact.
Safety of long-term cFVIIa expression in the AAV-treated hemophilic dogs
For personal use only. on January 3, 2018. by guest www.bloodjournal.org From Serum chemistries for liver and kidney functions prior to and after gene transfer were closely monitored throughout the study. Values of serum CPK, alkaline phosphatase (AP), total bilirubin, AST, ALT, GGTP were determined and found to be within the normal range in all dogs (Table 3) . AP levels for the HB-1-J10 dog was marginally elevated for the first 2 weeks, but this dog also had slightly raised AP levels even pre-AAV infusion (Table 3 ). Platelet (PLT) counts were within the normal range throughout the study ( Figure 3A) . Since mice continuously expressing mFVIIa at levels > 2µg/ml exhibited premature mortality 10 , in order to further address the safety of this gene transfer approach, we used three different assays: levels of thrombin-antithrombin (TAT) complex, D-dimer levels (elevated levels of which are indicators of thromboembolic disease and disseminated intravascular coagulation [DIC] in dogs 29, 30 ) and fibrinogen levels, elevated levels of which are associated with cardiovascular disease. 31 We did not detect any significant changes in TAT or D-dimer levels relative to pre-AAV administration (P>0.2) in any of the vector doses used in AAV-treated dogs throughout the observation period ( Figure 3B -C, respectively). Fibrinogen levels displayed some variability with time and 2 out of 4 dogs (HB-1-J10 and HA-1-J55) exhibited a transient (~1 week in duration) elevation, possibly due to a post-operative response to the administered analgesia pre and post-surgery, as previously described. 32 In any case, analysis of post-operative samples starting 1 week after the last prophylactic normal canine plasma infusion revealed fibrinogen levels that were within the normal range for HA and HB dogs (P>0.05 vs. untreated HB for the HB dog; P>0.12 vs. untreated HA for the HA-1-J55, HA-2-J57 and HA-3-E66 dogs; Figure 3D ). This was in agreement with the lack of significant changes in D-dimer levels observed ( Figure 3C ). Lastly, as Here, we provide proof-of-concept for this gene transfer approach using continuous expression of canine FVIIa in hemophilic dogs. This large animal model has been a good predictor for efficacy in hemophilia using a range of products. [12] [13] [14] [15] However, because FVIIa is a protease (in contrast to previous gene transfer approaches using zymogen FVIII or FIX), the issue of safety, especially with respect to thrombosis, is pertinent. Hence, our study focused on demonstrating both efficacy and safety and we
For personal use only. on January 3, 2018. by guest www.bloodjournal.org From report three major findings in hemophilic dogs: (1) canine FVII can be engineered for secretion in a biologically active, two chain form; (2) continuous expression of FVIIa at levels of ~2 µg/ml (~40 nM) can result in a marked, long-term improvement in the bleeding diathesis, despite only partial correction of in vitro hemostatic parameters, and (3) at these expression levels and administered AAV8 vector doses, we observed no hepatotoxicity or increased risk of thrombosis.
With respect to levels of expression necessary for efficacy, our results are similar to those obtained in hemophilic mice transgenic for murine FVIIa (mFVIIa) or following AAV-mFVIIa mediated gene transfer. 9, 10 An administered dose in the range of 6.25-12.5E13 v.g./kg led to sustained cFVIIa expression of 1.5-2.5 µg/ml resulting in supraphysiological reduction in the PT (as expected) and a partial or near correction of the WBCT and thromboelastography parameters, respectively. This suggests that in both animal models of hemophilia, hemostatic efficacy can be achieved at levels comparable to bolus rhFVIIa infusion in humans. However, the effective vector dose in hemophilic dogs was 2-5 fold higher than doses required in mice, resembling similar findings with canine FVIII (cFVIII) or FIX (cFIX). 33, 34 This observation thus justifies the use of this large animal model in preclinical gene transfer studies using FVIIa, as a predictor of efficacy in humans; it is worth noting that dogs, in contrast to mice, predicted the correct dosing in a human liver trial using an AAV-human FIX vector. 35 Moreover, the lack of clinically relevant endpoints in mouse studies such as the spontaneous bleeding episodes observed in hemophilic dogs, further underlines the value of the canine model of hemophilia. Indeed, we observed a complete lack of spontaneous bleeds in the AAVtreated hemophilic dogs throughout this study, a clear improvement in the bleeding The evident improvement in the bleeding diathesis has particular clinical importance with respect to a human application of this gene transfer approach. The major morbidity in hemophilia patients results from repeated bleeds into the joints. 38 If these result from damage in the joint microenvironment, it is conceivable that continuous expression of FVIIa may result in a reduced number of joint bleeds. We have previously
shown that continuous expression of mFVIIa at levels of 0.5-1.5 µg/ml in hemophilic mice resulted in restoration of hemostasis following a hemostatic challenge in the microcirculation, but not a challenge in the large vessels. 10 Hence, a potential explanation for the absence of spontaneous bleeds (including joint bleeds) in this study may be that continuous expression of FVIIa offers a "protective" and localized hemostatic effect, particularly in the microcirculation. Surprisingly, despite the lack of appreciable changes in the hemostatic parameters and cFVIIa levels in the treated HB-1 dog following lowdose AAV8-cFVIIa infusion, we only observed 3 non-spontaneous bleeds within the first 8 months post vector administration in an observation period of 34 months. Similar results in HA dogs receiving a low vector dose would be expected given the similarity of these two hemophilia models in response to rhFVIIa infusions. 12 The fact that AAVmediated, low vector dose FVIIa gene transfer may offer some clinical benefit certainly warrants further investigation in the dog model since it will be safe and may have potential application in prophylaxis. Such experiments in dogs, which are currently
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An important observation in hemophilic mice transgenic for mFVIIa was the premature mortality of mice continuously expressing mFVIIa at levels >2 µg/ml. 10 Since the dog model of hemophilia has been a good predictor of efficacy of hemophilia treatments, it was therefore pertinent in this study, where FVIIa is continuously An important observation of the current study is that the level of expression required for efficacy is higher in comparison to similar AAV-based, liver-directed approaches for hemophilia using cFVIII or cFIX, where phenotypic improvement was observed with as little as 4-9% of cFVIII (4-20 ng/ml 33, 40 , assuming 100-200 ng/ml is 100%) or 5% of cFIX (~250 ng/ml 22 , assuming 5 µg/ml is 100%). Consequently, the AAV8 vector doses used here were higher than used for AAV8-cFVIII (1E13 v.g./kg 40 ) or AAV8-cFIX (5.25E13/kg 41 ). However, this is not surprising; recombinant FVIIa has a substantially shorter half-life (~2.5 hours 42 ) than either recombinant FVIII (~12 hours 43 ) or FIX (~19 hours 44 ) and pharmacologic levels required for hemostatic efficacy are higher (as shown by bolus dosing of rhFVIIa compared to recombinant FVIII or FIX).
Clearly, a strategy to reduce the effective vector dose may be desirable and is currently underway, using a combination of improved AAV vectors 45 as well as optimization of GC-content, cis-regulatory elements and codon usage. 46 Moreover, complementary to improvements on the DNA level, changes on the protein level may also be implemented using high-activity variants of FVIIa. 47, 48 In conclusion, our data demonstrate that liver-directed, AAV8-mediated gene designed research and wrote the paper.
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